InspireMD (NASDAQ: NSPR) and Transenterix (NYSE:TRXC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

Analyst Ratings

This is a breakdown of current ratings for InspireMD and Transenterix, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
InspireMD 0 0 0 0 N/A
Transenterix 0 0 1 0 3.00

Transenterix has a consensus price target of $2.75, indicating a potential upside of 82.12%. Given Transenterix’s higher probable upside, analysts clearly believe Transenterix is more favorable than InspireMD.


This table compares InspireMD and Transenterix’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
InspireMD -358.44% -136.76% -94.77%
Transenterix -928.85% -49.16% -33.51%

Valuation and Earnings

This table compares InspireMD and Transenterix’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
InspireMD $2.00 million 1.36 -$8.37 million N/A N/A
Transenterix $5.05 million 44.41 -$47.82 million N/A N/A

InspireMD has higher revenue, but lower earnings than Transenterix.


Transenterix beats InspireMD on 6 of the 8 factors compared between the two stocks.

About InspireMD

InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.

About Transenterix

TransEnterix, Inc. is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera. The system features advanced technology to enable surgeons with haptic feedback and the ability to move the camera through eye movement. The system replicates laparoscopic motion and integrates three-dimensional high definition (3DHD) vision technology. The ALF-X System also offers responsible economics to hospitals by offering robotic technology with reusable instruments. The SurgiBot System is designed as a single-incision, patient-side robotic-assisted surgery system. The Company also develops and manufactures laparoscopic surgical instruments that are used in abdominal surgery, such as scissors, graspers, clip appliers, and suction and irrigation instruments.

Receive News & Ratings for InspireMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD Inc and related companies with's FREE daily email newsletter.